The investment in quality syringes pays for itself in dosing accuracy, especially when working with high-concentration formulations where small volume errors produce large dose variations
has received research support for the University of Florida as principal investigator from Boehringer Ingelheim, Echosens, Inventiva, LabCorp and Perspectum and has served as a consultant for Aligos Therapeutics, Arrowhead, AstraZeneca, 89bio, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Prosciento, Sagimet Biosciences, Siemens USA and Terns Pharmaceuticals
ELI LILLY CUTS COST OF CERTAIN ZEPBOUND DOSES BY AT LEAST 50% Eli Lilly told FOX Business it is also in discussions with the administration "to further expand patient access, preserve innovation and promote the affordability of our medicines." It declined to offer specific details about the discussion
The focus was on the logistics of moving the MDL forward